Tyr292
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr292  -  FCGR2B (human)

Site Information
GAENTITySLLMHPD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448507

In vivo Characterization
Methods used to characterize site in vivo:
phospho-antibody ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
mononuclear-blood ( 1 )

Upstream Regulation
Kinases, in vitro:
BLK (human) ( 3 ) , Fyn (human) ( 2 ) , LYN (human) ( 3 )
Treatments:
antibody ( 1 ) , palivizumab ( 1 )

Downstream Regulation
Effects of modification on FCGR2B:
molecular association, regulation ( 2 )
Induce interaction with:
SHP-2 (human) ( 2 )

References 

1

Iwata Y, et al. (2023) Preclinical in vitro evaluation of immune suppression induced by GYM329, Fc-engineered sweeping antibody. J Toxicol Sci 48, 399-409
37394653   Curated Info

2

Cochrane D, Webster C, Masih G, McCafferty J (2000) Identification of natural ligands for SH2 domains from a phage display cDNA library. J Mol Biol 297, 89-97
10704309   Curated Info

3

Bewarder N, et al. (1996) In vivo and in vitro specificity of protein tyrosine kinases for immunoglobulin G receptor (FcgammaRII) phosphorylation. Mol Cell Biol 16, 4735-43
8756631   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.